Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Therapeutics Cooke Pharma Buyout Provides Added Marketing/R&D

This article was originally published in The Tan Sheet

Executive Summary

United Therapeutics Corporation's acquisition of Cooke Pharma will give the HeartBar manufacturer a boost in marketing and research and development resources.

You may also be interested in...



FTC settles with HeartBar marketers

Unither Pharma and United Therapeutics will cease making certain ad claims for their L-arginine-containing HeartBar following FTC allegations the claims are unsupported by scientific evidence, according to 1June 12 settlement. Agreement prohibits multiple claims such as "HeartBar decreases leg pain, prevents age-related vascular problems, reduces the risk of cardiovascular disease and reduces or eliminates the need for surgery and medications among patients with" CVD, which appeared on 2Unither's Web site and in print ads, FTC says. United Therapeutics acquired HeartBar when it purchased Cooke Pharma in 2000 (3"The Tan Sheet" Jan. 1, 2001, p. 5)...

FTC settles with HeartBar marketers

Unither Pharma and United Therapeutics will cease making certain ad claims for their L-arginine-containing HeartBar following FTC allegations the claims are unsupported by scientific evidence, according to 1June 12 settlement. Agreement prohibits multiple claims such as "HeartBar decreases leg pain, prevents age-related vascular problems, reduces the risk of cardiovascular disease and reduces or eliminates the need for surgery and medications among patients with" CVD, which appeared on 2Unither's Web site and in print ads, FTC says. United Therapeutics acquired HeartBar when it purchased Cooke Pharma in 2000 (3"The Tan Sheet" Jan. 1, 2001, p. 5)...

FTC settles with HeartBar marketers

Unither Pharma and United Therapeutics will cease making certain ad claims for their L-arginine-containing HeartBar following FTC allegations the claims are unsupported by scientific evidence, according to 1June 12 settlement. Agreement prohibits multiple claims such as "HeartBar decreases leg pain, prevents age-related vascular problems, reduces the risk of cardiovascular disease and reduces or eliminates the need for surgery and medications among patients with" CVD, which appeared on 2Unither's Web site and in print ads, FTC says. United Therapeutics acquired HeartBar when it purchased Cooke Pharma in 2000 (3"The Tan Sheet" Jan. 1, 2001, p. 5)...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel